SION — Sionna Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2036042 ·
Last close
$42.88
Market Cap
$1.94B
52W High
$48.44
52W Low
$32.56
ADV30
435,959
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -29,599,000 | -26,779,000 | 305,039,000 | 63,324,000 | 16,831,000 |
| Dec 2025 | 0 | — | -23,612,000 | -20,440,000 | 325,953,000 | 58,451,000 | 19,120,000 |
| Sep 2025 | 0 | — | -23,805,000 | -20,278,000 | 339,270,000 | 50,831,000 | 17,602,000 |
| Jun 2025 | 0 | — | -21,906,000 | -18,068,000 | 352,048,000 | 40,985,000 | 15,619,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-66,297,000
Investing CF
$-118,749,000
Financing CF
$205,710,000
CapEx
$-377,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.95
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-256,354,000
Inventory
—
Receivables
—
ST Investments
$177,431,000
EBIT TTM
$-88,982,000
Pretax Income TTM
$-75,268,000
Interest Exp TTM
—
Analysts
10
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -88,982,000 | -75,268,000 | 325,953,000 | 19,120,000 | — | -66,297,000 |
| Dec 2024 | 0 | -70,556,000 | -61,688,000 | 185,752,000 | 349,465,000 | — | -52,787,000 |
| Dec 2023 | 0 | -50,333,000 | -47,263,000 | 51,945,000 | 166,826,000 | — | -43,699,000 |
| Dec 2022 | 0 | -41,372,000 | -40,240,000 | 87,369,000 | 157,293,000 | — | -36,068,000 |
TTM Snapshot
Revenues TTM
$2,566,000
NetIncome TTM
$-8,552,000
OpCashFlow TTM
$0
Assets (Latest)
$185,752,000
Forward EPS
$-2.80
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| STOK | Stoke Therapeutics, Inc. | $1.93B | $31.03 | — |
| AUPH | Aurinia Pharmaceuticals Inc. | $1.95B | $15.19 | — |
| RAPP | Rapport Therapeutics, Inc. | $1.90B | $39.71 | — |
| NBTX | Nanobiotix S.A. | $1.98B | $40.80 | — |
| AAPG | ASCENTAGE PHARMA GROUP INTERNATIONAL | $1.88B | $20.13 | — |
News headlines (Yahoo Finance, 1h cache)
Wedbush Initiates Coverage of Sionna Therapeutics (SION)
2026-05-14 16:52 · Yahoo
Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
2026-05-13 12:00 · Yahoo
Sionna Therapeutics Reports First Quarter 2026 Financial Results
2026-05-12 11:00 · Yahoo
A Look At Sionna Therapeutics (SION) Valuation After Its Strong 1 Year Return And Premium P/B Ratio
2026-05-05 14:11 · Yahoo
Sionna Insider Sells $2.5 Million in Stock Amid 215% Surge, but Here's What Investors Should Watch
2026-04-27 19:49 · Yahoo
Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis
2026-04-27 11:00 · Yahoo
Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium
2026-04-07 11:00 · Yahoo
Sionna Chief Legal Officer Cashed Out Her Shares. Her Options Are Another Story
2026-03-31 01:28 · Yahoo
Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet?
2026-03-18 15:49 · Yahoo
This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares
2026-03-15 22:27 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.